This question is important. In my opinion, these are two completely different things. The decline in the industry's investment in the pharmaceutical sector in Canada is due in large measure to emerging economies. In the pharmaceutical sector, developed countries are going to see annual growth of 1% to 2% over the next few years, whereas emerging countries will see growth expressed in two-digit numbers. In their case, we are looking at 14% or 15%. It is clear that the industry negotiates its investments here as though they were chips in a poker game. They offer such and such investments, and ask what will be given to them in return.
At this time, whatever Canada does, it is no longer a strategic market for the industry. It is clear that investments will be focused on emerging markets.
And yet the inclusion of these provisions in the free trade agreement is justified by saying that the real issue is the intellectual property system in Canada. According to the industry, revenues are insufficient in Canada and if they were higher, the industry would invest more in R&D.